Intraoperative Ketamine Versus Lidocaine Infusion on Postoperative Cognitive Dysfunction in Patients Undergoing Hip Surgery
Effect of Intraoperative Ketamine Versus Lidocaine Infusion on Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Hip Surgery
This study aims to compare effects of ketamine versus lidocaine on postoperative cognitive dysfunction in geriatric patient undergoing hip surgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Hip arthroplasty remains one of the most commonly used and successful contemporary surgical interventions performed in older adults. Hip fractures in the elderly have emerged as a serious injury that incurs high medical costs and public resources due to long-term bed rest, limitations of independent daily living, or death, more than 28,000 hip fractures occur annually; this number is rapidly rising with the aging population) .
Despite successful surgery, patients still may suffer short- or long-term postoperative cognitive dysfunction , due to long operative times, extensive trauma, and the possibility of fat emboli .
POCD, which reflects a negative change in an individual's cognitive trajectory, has increasingly been recognized as a complication in elderly patients. It is characterized by disturbances in consciousness, orientation, thinking, memory, and executive function after surgical anesthesia .
The potential pathogenesis of postoperative cognitive dysfunction involves neuroinflammation and oxidative stress secondary to anesthesia and surgery. Post-surgery inflammation is characterized by increased levels of inflammatory cytokines and mediators and vascular permeability. Excessive inflammation can disrupt the body's immune system, potentially leading to certain inflammation-related conditions .
postoperative cognitive dysfunction is a neurological dysfunction which may last for weeks, months or years and can delay recovery, extend hospital stays, and even increase patient mortality. The incidence of postoperative cognitive dysfunction varies between 20 and 40% in patients over 60 years old. Therefore, it is important to develop new strategies to prevent postoperative cognitive dysfunction , especially in elderly patients . However, there is still unclear. on the methods and treatments used to prevent and treat postoperative cognitive dysfunction , including dexmedetomidine, ketamine, ulinastatin, parecoxib, midazolam, lidocaine, and dexamethasone.
Systemic lidocaine possesses analgesic, antihyperalgesic, prokinetic, and anti-inflammatory properties. It inhibits the release of proinflammatory cytokines and superoxide anions from activated neutrophils and blocks their accumulation at the injury site. The use of intravenous lidocaine infusions is associated with better pain relief, decreased risk of postoperative ileus, and improved enhanced recovery after surgery outcomes .
Ketamine, a non-competitive antagonist of N-methyl-d-aspartate receptors, exerts its primary mechanism of action by blocking N-methyl-d-aspartate receptors on gamma-aminobutyric acid interneurons and activating alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Ketamine possesses anti-inflammatory properties, including the reduction of microglia activation as well as downregulation of pro-inflammatory cytokines . Hence, this study aims to compare effects of ketamine and lidocaine on postoperative cognitive dysfunction in geriatric hip surgery patients.
This study aims to compare effects of ketamine versus lidocaine on postoperative cognitive dysfunction in geriatric patient undergoing hip surgery.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tanta, Egypt
- Tanta University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Both sexes of Elderly patient Aged >65 years.
- American Society of Anesthesiologists classification I-III.
- Undergoing hip surgery under spinal anesthesia.
Exclusion Criteria:
- Patient refusal.
- History of mental illness or scoring less than 8 using abbreviated mental test before operation as in table 3 .
- Obvious sinus bradycardia (heart rate of <50 beats per minute) or other serious cardiovascular diseases.
- Symptomatic cerebrovascular disease (such as previous stroke).
- History of liver and kidney dysfunction.
- Allergy to lidocaine or ketamine.
- Metabolic disorders and fluid, electrolytes disturbances.
- Alcohol dependence or drug abuse.
- Redo surgery or infectious complications.
- Central nervous system medications (antipsychotics, anticonvulsants, antiparkinsonian, antidepressants).
- History of deep vein thrombosis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group Ketamine
Patients will receive ketamine as a bolus (0.5 mg/kg) after induction of spinal anesthesia, followed by a continuous infusion (0.2 mg/kg. h) until the end of surgery. |
Patients will receive ketamine as a bolus (0.5 mg/kg) after induction of spinal anesthesia, followed by a continuous infusion (0.2 mg/kg. h) until the end of surgery. |
|
Experimental: Group Lidocaine
Patients will receive lidocaine as a bolus (1.5 mg/kg) after induction of spinal anesthesia, followed by a continuous infusion (2 mg/kg. h) until the end of surgery. |
Patients will receive lidocaine as a bolus (1.5 mg/kg) after induction of spinal anesthesia, followed by a continuous infusion (2 mg/kg. h) until the end of surgery |
|
Placebo Comparator: Group Placebo
Patients will receive placebo (saline) and administered in equal volumes and in the same manner as a control group. |
Patients will receive placebo (saline) and administered in equal volumes and in the same manner as a control group. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of postoperative cognitive dysfunction
Time Frame: 3 days
|
3 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative pain score
Time Frame: 24 hours postoperatively
|
postoperative pain assessment with the Numerical rating Scale. Numerical rating Scale(0 represents "no pain") (1-3) mild pain; (4-6) moderate pain; (7-10) severe pain |
24 hours postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 36265MD386/3/25
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
It will be available if it needed
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.